Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00522925 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension
A Phase 2 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
NCT00522925: Completed Phase 2 study, sponsored by Ligand Pharmaceuticals.
NCT00522925 is a Phase 2 study that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 280 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (111% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00522925, a Phase 2 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
Study Summary
The purpose of the study is to see if PS433540 lowers blood pressure better than placebo and to see how safe PS433540 is compared to placebo.
Interventions
- DRUG placebo
- DRUG PS433540
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
What the finished NCT00522925 record still lists
NCT00522925 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (111% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00522925 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00522925 about?
NCT00522925 is a clinical study titled "A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension". The purpose of the study is to see if PS433540 lowers blood pressure better than placebo and to see how safe PS433540 is compared to placebo.
What is the current status of trial NCT00522925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2007-08. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00522925?
The interventions under investigation include: placebo (DRUG), PS433540 (DRUG).
Who is sponsoring clinical trial NCT00522925?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00522925's enrollment target sits among peer trials
280 196th of 2000 higher than 1,800 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia